Our choice of inclusion of KRAS as an actionable target relates to the fact that there are early ongoing trials focused on downstream targeting of the MAPK pathway in KRAS mutant patients [17, 18], making it a potentially actionable target in some tumor types. The gene discussed is KRAS; the disease is neoplasm.